ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1812

C3 Glomerulopathy Recurrence After Kidney Transplant: A Systematic Review

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Taroua, Oumayma, Universite Internationale Abulcasis des Sciences de la Sante, Rabat, Rabat-Sale-Kenitra, Morocco

C3 glomerulopathy (C3G) is a recently defined entity, characterized by the dysregulation of the complement pathway, leading to deposition of C3 complement in the glomeruli, with no or few immunoglobulin deposits. While it is known that membranoproliferative glomerulopathies carry a risk of recurrence after transplant, no large-scale meta-analysis was done after 2015 to assess the precise recurrence risk and remission duration for C3 glomerulopathies. The goal of this work is to determine if there is currently enough literature specific for C3G to conduct such a metanalysis.


Our research protocol was guided by the PRISMA protocol, and the Joanna Briggs Institute Critical Appraisal Tools. A search was conducted in 3 databases using a specific search string, at the conclusion of which, 230 papers were found. The identified papers were subsequently screened by the 2 authors independently using precise inclusion and exclusion criteria. The screening resulted in the final inclusion of 6 papers, on which a qualitative synthesis was performed. The information extracted was organized on the basis of demographics, time of transplantation, disease recurrence, and disease-free period post-transplantation.


Among the 6 papers selected, 2 were case series and 4 were case reports. In total, 25 patients were reported as having a recurrence of C3G. The age of the patients ranged between 7 and 60 years of age. Among the 25 patients, 11 of them were male, while 6 of them were females. The C3G subtype was determined for 25 patients, with 16 were classified as having C3GN. and 8 having DDD. The age of transplant was reported for 14 patients, ranging from 11 to 64 years old. The disease-free period between the kidney transplant and the recurrence of the disease ranged from 14 days to 91 months, with 1 case series paper only reported the median time to recurrence in months (59[27-91] for C3GN patients and 41[0-71] for DDD patients).


While C3G, with its 2 subtypes, have been well-defined entities for a decade, our review reveals that little research about the post-transplant evolution and recurrence of these diseases has been done. While extensive research can be found on the recurrence risks of Membranoproliferative Glomerulonephritis, we believe that with the new classification, more data on the new subtypes is necessary to guide the decision-making of clinicians and their patients.